CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Publication date: July 2021Source: The Lancet Haematology, Volume 8, Issue 7Author(s): Jeffrey E Lancet, Geoffrey L Uy, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen A Strickland, Donna Hogge, Scott R Solomon, Dale L Bixby, Jonathan E Kolitz, Gary J Schiller, Matthew J Wieduwilt, Daniel H Ryan, Stefan Faderl, Jorge E Cortes
Source: The Lancet Haematology - Category: Hematology Source Type: research